Investors’ data
Latest news
- July 10, 2008
Thallion Announces 2008 Second Quarter Results
- July 7, 2008
Notice of Thallion Pharmaceuticals Fiscal 2008 Second Quarter Conference Call
- June 26, 2008
Thallion receives health canada approval to initiate Phase II study for TLN-232 in metastatic melanoma patients- Company initiates Phase II study with its second oncology product -
Documentation
Corporate Governance
Thallion Pharmaceutical Inc. and its Board of Directors believe that transparent and sound corporate governance practices are critical to the Company’s long-term success.
The Board believes that the Company’s corporate governance practices are well aligned with the recommendations contained in the various applicable guidelines and regulations issued by the Toronto Stock Exchange (TSX Guidelines) and other securities regulators.
For further information, please refer to our corporate profile on SEDAR.